JNJ Johnson & Johnson
Healthcare · Drug Manufacturers - General
259.80
-0.77%
About the company
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
52-week range
Dividend deep dive
Johnson & Johnson (JNJ) is a healthcare sector company specializing in drug manufacturing with a market capitalization of USD 624.26 billion. The company currently provides a dividend yield of 2.13%. This yield is below its 5-year average of 2.88%, with yield theory suggesting an "overvalued" status for the stock. Despite this, Johnson & Johnson's dividend safety status is assessed as "safe".
Dividend history
Johnson & Johnson has demonstrated a consistent dividend growth record, earning it a "Champion" tier classification with 29 consecutive years of dividend increases. The dividend has grown at a 3-year Compound Annual Growth Rate (CAGR) of 4.78% and a 5-year CAGR of 5.18%. Dividends are distributed quarterly in March, June, September, and December. Annual dividends per share have increased steadily from USD 2.80 in 2014 to USD 4.96 in 2024, with a projected USD 5.20 for 2025.
Dividend safety
Johnson & Johnson's dividend is rated as "safe." The company maintains a payout ratio of 62.18% based on its current dividend and earnings per share. Its debt-to-equity ratio is 67.73%. Current and quick ratio figures were not provided.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 23 investors · watched by 5
Appears in these lists
JNJ qualifies for these curated dividend rankings.
Appears in these comparisons
See how JNJ stacks up against its dividend rivals.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track JNJ and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →